Table 2.
Diagnostic performance of Banff AM-VR criteria with use of arterial C4d
| Parameters | Sensitivity | Specificity | PPV | NPV |
|---|---|---|---|---|
| AM-VR test criteria | ||||
| Banff 2019 (C4dptc only), % | 57.9 | 95.4 | 94.3 | 63.1 |
| 95% CI | 44.1–70.9 | 84.2–99.4 | 80.7–98.5 | 55.6–70.0 |
| Expanded Banff criteria (C4dptc and C4dart), % | 93.0 | 90.2 | 92.9 | 90.7 |
| 95% CI | 83.0–98.1 | 77.8–97.4 | 3.9–97.1 | 79.0–96.2 |
AM-VR, antibody-mediated vascular rejection; C4dptc, C4d staining of peritubular capillaries; C4dart, C4d staining of arterial endothelium and intima; PPV, positive predictive value; NPV, negative predictive value.
The test performances of the Banff 2019 AM-VR criteria using conventional C4dptc and expanded diagnostic criteria allowing C4dart (using immunoperoxidase) as evidence endothelial-antibody interaction against an independent clinical-pathologic reference standard are derived from all VR cases (n = 100 biopsies).
Results are percentages, 95% CI below.